Skip to main content
. 2017 Jul 12;199(4):1465–1475. doi: 10.4049/jimmunol.1602151

FIGURE 3.

FIGURE 3.

TRPV1 mediates NADA anti-inflammatory activity in mice challenged with LPS or Pam3Cys. WT and Trpv1−/− mice were challenged i.v. with LPS (A–D) or Pam3Cys (E–H) and immediately thereafter were treated i.v. with NADA or vehicle (n = 4 mice per group). Plasma concentrations of IL-6 (A and E), CCL2 (B and F), IL-10 (C and G), and PAI-1 (D and H) were quantified at 2 h. There were no significant differences between WT and Trpv1−/− mice challenged with LPS or Pam3Cys in the absence of NADA or in WT and Trpv1−/− mice treated with NADA alone (data not shown). **p < 0.01, LPS-challenged (A–D) or Pam3Cys-challenged (E–H) WT mice treated with NADA versus carrier, Mann–Whitney U test. NS, no significant difference between LPS-challenged or Pam3Cys-challenged Trpv1−/− mice treated with NADA versus carrier.